Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma

Luciano Costa, MD, PhD; Jing Christine Ye, MD, MSc; Samer Al Hadidi, MD, MS; and Binod Dhakal, MD, discuss how the multiple myeloma treatment landscape has evolved with quadruplet therapies becoming standard for newly diagnosed patients regardless of transplant eligibility, CAR T and bispecific antibodies showing promise for earlier use in relapsed/refractory disease, and emerging dual-targeting therapies potentially offering cure for some patients rather than just prolonged treatment.